SEARCH

SEARCH BY CITATION

References

  • 1
    Carlsson R, Dent J, Bolling-Sternevald E, et al. The usefulness of a structured questionnaire in the assessment of symptomatic gastroesophageal reflux disease. Scand J Gastroenterol 1998; 33: 10239.
  • 2
    Armstrong D. Diagnostic significance, provocants and time-course of heartburn and regurgitation. Eur J Gastroenterol Hepatol 2001; 13(Suppl. 3): S213.
  • 3
    Dent J, Brun J, Fendrick AM, et al. An evidence-based appraisal of reflux disease management: the Genval Workshop Report. Gut 1999; 44(Suppl. 2): S16.
  • 4
    Venables TL, Newland RD, Patel AC, et al. Omeprazole 10 milligrams once daily, omeprazole 20 mg once daily, or ranitidine 150 mg twice daily, evaluated as initial therapy for the relief of symptoms of gastro-esophageal reflux disease in general practice. Scand J Gastroenterol 1997; 32: 96573.
  • 5
    Carlsson R, Galmiche J-P, Dent J, Lundell L, Frison L. Gastro-esophageal reflux disease in primary care: an international study of different treatment strategies with omeprazole. Eur J Gastroenterol Hepatol 1997; 10: 11924.
  • 6
    Lind T, Havelund T, Carlsson R, et al. Heartburn without oesophagitis: efficacy of omeprazole therapy and features determining therapeutic response. Scand J Gastroenterol 1997; 32: 9749.
  • 7
    Galmiche JP, Barthelemy P, Hamelin B. Treating the symptoms of gastro-oesophageal reflux disease: a double-blind comparison of omeprazole and cisapride. Aliment Pharmacol Ther 1997; 11: 76573.
  • 8
    Castell DO, Kahrilas PJ, Richter JE, et al. Esomeprazole (40 mg) compared with lansoprazole (30 mg) in the treatment of erosive esophagitis. Am J Gastroenterol 2002; 97: 57583.
    Direct Link:
  • 9
    Richter JE, Kahrilas PJ, Johanson J, et al. Efficacy and safety of esomeprazole compared with omeprazole in GERD patients with erosive esophagitis: a randomized controlled trial. Am J Gastroenterol 2001; 96: 65665.
    Direct Link:
  • 10
    Kahrilas PJ, Falk GW, Johnson DA, et al. Esomeprazole improves healing and symptom resolution as compared with omeprazole in reflux oesophagitis patients: a randomized controlled trial. The Esomeprazole Study Investigators. Aliment Pharmacol Ther 2000; 14: 124958.
  • 11
    Armstrong D, Paré P, Pericak D, Pyzyk M, Canadian Pantoprazole GERD Study Group. Symptom relief in gastroesophageal reflux disease: a randomized, controlled comparison of pantoprazole and nizatidine in a mixed patient population with erosive esophagitis or endoscopy-negative reflux disease. Am J Gastroenterol 2001; 96: 284957.
  • 12
    Bate CM, Green JR, Axon AT, et al. Omeprazole is more effective than cimetidine for the relief of all grades of gastro-oesophageal reflux disease-associated heartburn, irrespective of the presence or absence of endoscopic oesophagitis. Aliment Pharmacol Ther 1997; 11: 75563.
  • 13
    Goves J, Oldring JK, Kerri D, et al. First line treatment with omeprazole provides an effective and superior alternative strategy in the management of dyspepsia compared to antacid/alginate liquid: a multicentre study in general practice. Aliment Pharmacol Ther 1998; 12: 14757.
  • 14
    Mason I, Millar LJ, Sheikh R, et al. The management of acid-related dyspepsia in general practice: a comparison of an omeprazole versus antacid-alginate/ranitidine management strategy. Aliment Pharmacol Ther 1998; 12: 26371.
  • 15
    Meineche-Schmidt V, Krag E. Antisecretory therapy in 1017 patients with ulcer-like or reflux-like dyspepsia in general practice. Eur J Gen Pract 1997; 3: 12530.
  • 16
    Jones RH, Baxter G. Lansoprazole 30 mg daily versus ranitidine 150 mg bd in the treatment of acid-related dyspepsia in general practice. Aliment Pharmacol Ther 1997; 11: 5416.
  • 17
    Thomson ABR, Barkun AN, Armstrong D, et al. The prevalence of clinically significant endoscopic findings in primary care patients with uninvestigated dyspepsia: the Canadian Adult Dyspepsia Empiric Treatment – Prompt Endoscopy (CADET–PE) study. Aliment Pharmacol Ther 2003; 17: 148191.
  • 18
    Veldhuyzen van Zanten SJO, Flook N, Chiba N, et al. An evidence-based approach to the management of uninvestigated dyspepsia in the era of Helicobacter pylori. CMAJ 2000; 162(Suppl. 12): S123.
  • 19
    Chiba N, De Gara CJ, Wilkinson JM, Hunt RH. Speed of healing and symptom relief in grade II to IV gastroesophageal reflux disease: a meta-analysis. Gastroenterology 1997; 112: 1798810.
  • 20
    Caro JJ, Salas M, Ward A. Healing and relapse rates in gastroesophageal reflux disease treated with the newer proton-pump inhibitors lansoprazole, rabeprazole, and pantoprazole compared with omeprazole, ranitidine, and placebo: evidence from randomized clinical trials. Clin Ther 2001; 23: 9981017.
  • 21
    Hatlebakk JG, Hyggen A, Madsen PH, et al. Heartburn treatment in primary care: randomised, double blind study for 8 weeks. Br Med J 1999; 319: 5503.
  • 22
    De Vault KR, Castell DO. Updated guidelines for the diagnosis and treatment of gastro-esophageal reflux disease. The Practice Parameters Committee of the American College of Gastroenterology. Am J Gastroenterol 1999; 94: 143442.
  • 23
    Beck IT, Champion MC, Lemire S, Thomson ABR, and contributing participants. The second Canadian consensus conference on the management of patients with gastroesophageal reflux disease. Can J Gastroenterol 1997; 11(Suppl. B): 7B20B.
  • 24
    Ofman JJ, Dorn GH, Fennerty MB, et al. The clinical and economic impact of competing management strategies for gastro-esophageal reflux disease. Aliment Pharmacol Ther 2002; 16: 26173.
  • 25
    Gerson LB, Robbins AS, Garber A, et al. A cost-effectiveness analysis of prescribing strategies in the management of gastroesophageal reflux disease. Am J Gastroenterol 2000; 95: 395407.
    Direct Link:
  • 26
    Manning AP, Thompson WG, Heaton KW, et al. Towards positive diagnosis of the irritable bowel. Br Med J 1978; 2: 6534.
  • 27
    Chiba N, Veldhuyzen van Zanten SJO, Sinclair P, et al. Treating Helicobacter pylori infection in primary care patients with uninvestigated dyspepsia: the Canadian Adult Dyspepsia Empiric Treatment –Helicobacter Pylori positive (CADET-Hp) randomised controlled trial. Br Med J 2002; 324: 10126.
  • 28
    Veldhuyzen van Zanten SJO, Chiba N, Armstrong D, et al. A double-blind randomised controlled trial comparing omeprazole, ranitidine, cisapride and placebo in 512 Helicobacter pylori (Hp) negative primary care patients with uninvestigated dyspepsia (UD) – the CADET HN study. Can J Gastroenterol 2002; 16(Suppl. A): A5.
  • 29
    Veldhuyzen van Zanten SJO, Chiba N, Armstrong D, et al. The responsiveness of the Global Overall Symptom (GOS) score – a 7-point Likert scale for the measurement of dyspepsia symptoms in clinical trials. Can J Gastroenterol 2003; 17(Suppl. A): 113A.
  • 30
    Wiklund IK, Junghard O, Grace E, et al. Quality of life in reflux and dyspepsia patients. Psychometric documentation of a new disease-specific questionnaire (QOLRAD). Eur J Surg 1998; 583: 419.
  • 31
    Svedlund J, Sjödin I, Dötevall G. GSRS – clinical rating scale for gastrointestinal symptoms in patients with irritable bowel syndrome and peptic ulcer disease. Dig Dis Sci 1988; 33: 12934.
  • 32
    Juniper EF, Guyatt GH, Willan A, et al. Determining a minimal important change in a disease-specific quality of life questionnaire. J Clin Epidemiol 1994; 47: 817.
  • 33
    Armstrong D, Barkun AN, Chiba N, et al. On demand therapy for heartburn-dominant uninvestigated dyspepsia in primary care practice: the CADET-HR study. Can J Gastroenterol 2003; 17(Suppl. A): 105A.
  • 34
    Armstrong D, Bennett JR, Blum AL, et al. The endoscopic assessment of esophagitis: a progress report on observer agreement. Gastroenterology 1996; 111: 8592.
  • 35
    Lundell LR, Dent J, Bennett JR, et al. Endoscopic assessment of oesophagitis: clinical and functional correlates and further validation of the Los Angeles classification. Gut 1999; 45: 17280.
  • 36
    Locke GR III, Talley NJ, Fett SL, Zinsmeister AR, Melton LJ III. Prevalence and clinical spectrum of gastroesophageal reflux: a population-based study in Olmsted County, Minnesota. Gastroenterology 1997; 112: 144856.
  • 37
    Nebel OT, Fornes MF, Castell DO. Symptomatic gastro-esophageal reflux: incidence and precipitating factors. Am J Dig Dis 1976; 21: 9536.
  • 38
    Tougas G, Chen Y, Hwang P, et al. Prevalence and impact of upper gastrointestinal symptoms in the Canadian population: findings from the DIGEST study. Am J Gastroenterol 1999; 94: 284554.
    Direct Link:
  • 39
    Talley NJ, Weaver AL, Zinsmeister AR, Melton LJ III. Onset and disappearance of gastrointestinal symptoms and functional gastrointestinal disorders. Am J Epidemiol 1992; 136: 16577.
  • 40
    American Gastroenterological Association (AGA) Clinical Practice and Practice Economics Committee. AGA technical review: evaluation of dyspepsia. Gastroenterology 1998; 114: 58295.
  • 41
    Carlsson R, Galmiche JP, Dent J, Lundell L, Frison L. Prognostic factors influencing relapse of oesophagitis during maintenance therapy with antisecretory drugs: a meta-analysis of long-term omeprazole trials. Aliment Pharmacol Therap 1997; 11: 47382.
  • 42
    Bardhan KD, Müller-Lissner S, Bigard MA, et al. Symptomatic gastro-oesophageal reflux disease: double blind controlled study of intermittent treatment with omeprazole or ranitidine. The European Study Group. Br Med J 1999; 318: 5027.
  • 43
    Hetzel DJ, Dent J, Reed WD, et al. Healing and relapse of severe peptic esophagitis after treatment with omeprazole. Gastroenterology 1988; 95: 90312.
  • 44
    Sandmark S, Carlsson R, Fausa O, Lundell L. Omeprazole or ranitidine in the treatment of reflux esophagitis. Results of a double-blind, randomized, Scandinavian multicenter study. Scand J Gastroenterol 1988; 23: 62532.
  • 45
    Robinson M, Earnest D, Maton PN, et al. Frequent heartburn symptoms should not be ignored in subjects who self-treat with antacids. Gastroenterology 1996; 110: A241.
  • 46
    Armstrong D. Motion – all patients with GERD should be offered once in a lifetime endoscopy: arguments for the motion. Can J Gastroenterol 2002; 16: 54951.
  • 47
    Lagergren J, Bergstrom R, Lindgren A, Nyren O. Symptomatic gastroesophageal reflux as a risk factor for esophageal adenocarcinoma. N Engl J Med 1999; 340: 82531.
  • 48
    Armstrong D. Symptom status as a surrogate for absence of endoscopic oesophagitis. Eur J Gastroenterol Hepatol 2001; 13(Suppl. 3): S768.
  • 49
    van Pinxteren B, Numans ME, Lau J, de Wit NJ, Hungin APS, Bonis PAL. Short-term treatment of gastroesophageal reflux disease. A systematic review and meta-analysis of the effect of acid-suppressant drugs in empirical treatment and in endoscopy-negative patients. J Gen Intern Med 2003; 18: 75563.
  • 50
    Richter JE, Campbell DR, Kahrilas PJ, Huang B, Fludas C. Lansoprazole compared with ranitidine for the treatment of nonerosive gastroesophageal reflux disease. Arch Int Med 2000; 160: 18039.
  • 51
    Holtmann G, Cain C, Malfertheiner P. Gastric Helicobacter pylori infection accelerates healing of reflux esophagitis during treatment with the proton pump inhibitor pantoprazole. Gastroenterology 1999; 117: 116.
  • 52
    Wiklund I, Glise H, Jerndal P, Carlsson J, Talley NJ. Does endoscopy have a positive impact on quality of life in dyspepsia? Gastrointest Endosc 1998; 47: 44954.
  • 53
    Bytzer P, Hansen JM, Schaffalitzky Muckadell de OB. Empirical H2-blocker therapy or prompt endoscopy in management of dyspepsia. Lancet 1994; 343: 8116.
  • 54
    Acquadro C, Berzon R, Dubois D, et al. Incorporating the patient's perspective into drug development and communication: an ad hoc task force report of the Patient-Reported Outcomes (PRO) Harmonization Group meeting at the Food and Drug Administration. Value in Health 2003; 6: 52231.
  • 55
    Madisch A, Kulich KR, Malfertheiner P, et al. Impact of reflux disease on general and disease-related quality of life – evidence from a recent comparative methodological study in Germany. Z Gastroenterol 2003; 41: 113743.
  • 56
    Jones R, Horbach S, Sander P, Ryden-Bergsten T. Heartburn in patients with gastro-oesophageal reflux disease in Germany and Sweden: a study on patients’ burden of disease. Pharmacoeconomics 2003; 21: 1091102.
  • 57
    Havelund T, Lind T, Wiklund I, et al. Quality of life in patients with heartburn but without esophagitis: effects of treatment with omeprazole. Am J Gastroenterol 1999; 94: 17829.
    Direct Link:
  • 58
    Howden CW, Henning JM, Huang B, Lukasik N, Freston JW. Management of heartburn in a large, randomized, community-based study: comparison of four therapeutic strategies. Am J Gastroenterol 2001; 96: 170410.
    Direct Link:
  • 59
    Carlsson R, Bolling-Sternevald E, Jerndal P, et al. Factors predicting response to omeprazole treatment in patients with functional dyspepsia. Gastroenterology 1996; 110: A76.
  • 60
    Raghunath A, Hungin APS, Wooff D, Childs S. Prevalence of Helicobacter pylori in patients with gastro-oesophageal reflux disease: systematic review. Br Med J 2003; 326: 73743.
  • 61
    Harvey RF, Lane JA, Murray LJ, Harvey IM, Donovan JL, Nair P. Randomised controlled trial of effects of Helicobacter pylori infection and its eradication on heartburn and gastro-oesophageal reflux: Bristol Helicobacter project. Br Med J 2004; 328: 14179.